Neutropenia - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 93
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N536B6E66D9EN
Leaflet:

Download PDF Leaflet

Neutropenia - Pipeline Review, H2 2016
Neutropenia - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Neutropenia - Pipeline Review, H2 2016’, provides an overview of the Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Neutropenia
  • The report reviews pipeline therapeutics for Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Neutropenia therapeutics and enlists all their major and minor projects
  • The report assesses Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Neutropenia
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Neutropenia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Neutropenia Overview
Therapeutics Development
Pipeline Products for Neutropenia - Overview
Neutropenia - Therapeutics under Development by Companies
Neutropenia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Neutropenia - Products under Development by Companies
Neutropenia - Companies Involved in Therapeutics Development
Apotex Inc.
BeyondSpring Pharmaceuticals, Inc.
Biogenomics Limited
Cellerant Therapeutics, Inc.
Cleveland BioLabs, Inc.
Coherus BioSciences, Inc.
Dr. Reddy's Laboratories Limited
Eurofarma Laboratorios S.A.
Ligand Pharmaceuticals, Inc.
NAL Pharmaceuticals Ltd.
Prolong Pharmaceuticals, LLC
Richter Gedeon Nyrt.
Sandoz International GmbH
Therapeutic Proteins International, LLC
Toko Pharmaceutical Industries Co., Ltd.
USV Pvt Ltd
Neutropenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACN-8337 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBLB-612 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-18 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LG-7455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plinabulin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romyelocel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamibarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neutropenia - Dormant Projects
Neutropenia - Product Development Milestones
Featured News & Press Releases
Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case
Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (pegfilgrastim) Patent Case
Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study
May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication
Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701
Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program
Dec 08, 2015: EMA started the evaluation of Richter’s marketing authorisation application for biosimilar pegfilgrastim
Dec 07, 2015: Phase III Data Shows Sandoz’ Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product
Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
Oct 01, 2015: Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study
Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
Feb 17, 2015: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


LIST OF TABLES

Number of Products under Development for Neutropenia, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Neutropenia - Pipeline by Apotex Inc., H2 2016
Neutropenia - Pipeline by BeyondSpring Pharmaceuticals, Inc., H2 2016
Neutropenia - Pipeline by Biogenomics Limited, H2 2016
Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016
Neutropenia - Pipeline by Cleveland BioLabs, Inc., H2 2016
Neutropenia - Pipeline by Coherus BioSciences, Inc., H2 2016
Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
Neutropenia - Pipeline by Eurofarma Laboratorios S.A., H2 2016
Neutropenia - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
Neutropenia - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
Neutropenia - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016
Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016
Neutropenia - Pipeline by Sandoz International GmbH, H2 2016
Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H2 2016
Neutropenia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2016
Neutropenia - Pipeline by USV Pvt Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Neutropenia - Dormant Projects, H2 2016
Neutropenia - Dormant Projects (Contd.1), H2 2016

LIST OF FIGURES

Number of Products under Development for Neutropenia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Apotex Inc.
BeyondSpring Pharmaceuticals, Inc.
Biogenomics Limited
Cellerant Therapeutics, Inc.
Cleveland BioLabs, Inc.
Coherus BioSciences, Inc.
Dr. Reddy's Laboratories Limited
Eurofarma Laboratorios S.A.
Ligand Pharmaceuticals, Inc.
NAL Pharmaceuticals Ltd.
Prolong Pharmaceuticals, LLC
Richter Gedeon Nyrt.
Sandoz International GmbH
Therapeutic Proteins International, LLC
Toko Pharmaceutical Industries Co., Ltd.
USV Pvt Ltd
Skip to top


Febrile Neutropenia - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 60 pages
Febrile Neutropenia - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 61 pages
Neutropenia - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 77 pages
Encephalomyelitis - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 47 pages

Ask Your Question

Neutropenia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: